Aprea Therapeutics, Inc.
APREHealthcare|Biotechnology|US
$0.52
+0.02 (+4.50%)
DCF Value
$2.14
Tangible Book / Share
$0.64
Cash / Share
$0.71
Financials
Financial Snapshot
Market Cap
$6.5M
Enterprise Value
-$31.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$14.1M
Cash & Investments
$37.8M
Net Cash
$37.8M
Free Cash Flow (TTM)
-$12.7M
Operating CF (TTM)
-$12.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$37.8M
Quarterly Burn
$3.2M
Monthly Burn
$1.1M
Est. Runway
~11.9 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $24.4M | $65.7M | $130.1M | $89.0M | $53.1M | $28.8M | $21.6M | $22.8M | $14.6M | $37.8M | |
| Operating Cash Flow | -$14.0M | -$15.3M | -$26.7M | -$41.8M | -$37.7M | -$25.0M | -$12.2M | -$13.6M | -$12.9M | -$12.7M | |
| Free Cash Flow | -$14.0M | -$15.3M | -$26.7M | -$41.8M | -$37.7M | -$25.0M | -$12.3M | -$13.6M | -$12.9M | -$12.7M | |
| Capital Expenditure | $0.00 | -$3.7K | -$30.9K | -$25.7K | $0.00 | $0.00 | -$93.1K | -$15.5K | $0.00 | -$15.4K | |
| Financing Cash Flow | $23.3M | $56.4M | $92.6M | $150.9K | $1.7M | $683.0K | $5.1M | $14.8M | $4.6M | $36.9M |
R&D Spending
R&D (TTM)
$8.4M
R&D Intensity
—
R&D Growth vs Prior
+19.6%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $583.2K | $1.5M | $0.00 | $0.00 | |
| R&D Expense | $13.4M | $14.2M | $21.0M | $37.9M | $23.9M | $92.4M | $7.6M | $9.4M | $7.0M | $8.4M | |
| R&D % of Revenue | — | — | — | — | — | — | 1307.8% | 623.2% | — | — | |
| SG&A | $2.5M | $2.3M | $8.4M | $14.9M | $13.6M | $21.0M | $8.4M | $6.5M | $6.5M | $6.9M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $583.2K | $1.5M | $0.00 | $0.00 | |
| Cost of Revenue | $7.9K | $8.3K | $170.3K | $229.6K | $271.7K | $16.4M | $7.1K | $9.4M | $0.00 | $11.3K | |
| Gross Profit | -$7.9K | -$8.3K | -$170.3K | -$229.6K | -$271.7K | -$16.4M | $576.2K | -$7.9M | $0.00 | -$11.3K | |
| R&D | $13.4M | $14.2M | $21.0M | $37.9M | $23.9M | $92.4M | $7.6M | $9.4M | $7.0M | $8.4M | |
| SG&A | $2.5M | $2.3M | $8.4M | $14.9M | $13.6M | $21.0M | $8.4M | $6.5M | $6.5M | $6.9M | |
| Operating Income | -$15.9M | -$16.5M | -$29.5M | -$52.8M | -$37.4M | -$113.4M | -$15.5M | -$14.3M | -$13.2M | -$15.3M | |
| Interest Expense | $15.00 | $182.00 | $156.4K | $222.7K | $0.00 | $448.7K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$15.2M | -$15.5M | -$28.1M | -$53.5M | -$37.1M | -$112.7M | -$14.3M | -$13.0M | -$12.6M | -$14.1M | |
| Net Income | -$15.2M | -$15.5M | -$28.1M | -$53.9M | -$36.5M | -$112.7M | -$14.3M | -$13.0M | -$12.6M | -$14.1M | |
| EPS (Diluted) | -21.58 | -22.06 | -26.28 | -50.61 | -34.88 | -1359.79 | -3.95 | -2.35 | -1.93 | -0.70 | |
| EBITDA | -$15.2M | -$15.5M | -$27.9M | -$53.2M | -$36.9M | -$37.2M | -$14.3M | -$12.9M | -$12.6M | -$14.5M | |
| Shares Out. (M) | 0.70 | 0.70 | 1.00 | 1.06 | 1.06 | 0.08 | 3.62 | 5.51 | 6.54 | 53.68 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.4M | $65.7M | $130.1M | $89.0M | $53.1M | $28.8M | $21.6M | $22.8M | $14.6M | $37.8M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $24.7M | $66.0M | $133.0M | $92.4M | $56.6M | $30.2M | $22.5M | $23.6M | $15.6M | $38.4M | |
| Total Assets | $24.8M | $66.0M | $133.6M | $92.8M | $56.8M | $30.2M | $22.7M | $24.0M | $15.9M | $38.8M | |
| Total Current Liabilities | $4.3M | $4.9M | $9.1M | $15.3M | $7.3M | $3.2M | $4.4M | $3.4M | $2.8M | $4.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $60.5M | $117.5M | $9.4M | $15.4M | $7.3M | $4.5M | $4.4M | $4.7M | $3.5M | $4.7M | |
| Stockholders' Equity | -$35.8M | -$51.4M | $124.2M | $77.4M | $49.5M | $25.6M | $18.3M | $19.3M | $12.4M | $34.1M | |
| Retained Earnings | -$46.9M | -$62.5M | -$90.5M | -$144.0M | -$181.1M | -$293.8M | -$308.1M | -$321.0M | -$333.6M | -$345.3M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.0M | -$15.3M | -$26.7M | -$41.8M | -$37.7M | -$25.0M | -$12.2M | -$13.6M | -$12.9M | -$12.7M | |
| Capital Expenditure | $0.00 | -$3.7K | -$30.9K | -$25.7K | $0.00 | $0.00 | -$93.1K | -$15.5K | $0.00 | -$15.4K | |
| Free Cash Flow | -$14.0M | -$15.3M | -$26.7M | -$41.8M | -$37.7M | -$25.0M | -$12.3M | -$13.6M | -$12.9M | -$12.7M | |
| Investing Cash Flow | $0.00 | -$3.7K | -$30.9K | -$25.7K | $0.00 | $0.00 | -$93.1K | -$15.5K | $0.00 | -$15.7K | |
| Financing Cash Flow | $23.3M | $56.4M | $92.6M | $150.9K | $1.7M | $683.0K | $5.1M | $14.8M | $4.6M | $36.9M | |
| Issuance of Stock | $23.3M | $56.4M | $86.9M | $150.9K | $1.5M | $683.0K | $5.8M | $16.1M | $5.0M | $39.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $395.4K | $329.2K | $1.3M | $5.0M | $7.8M | $17.0M | $444.5K | $489.4K | $478.1K | $412.0K | |
| Net Change in Cash | $10.7M | $41.3M | $64.4M | -$41.1M | -$35.9M | -$24.3M | -$7.1M | $1.2M | -$8.2M | $24.1M |
Dilution Tracker
Shares outstanding grew 518.8% over 5 years — significant dilution
Shares Outstanding
13M
5-Year Share Growth
+518.8%
Stock Issuance (TTM)
$39.8M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.70 | 0.70 | 1.00 | 1.06 | 1.06 | 0.08 | 3.62 | 5.51 | 6.54 | 53.68 | |
| Change vs Prior % | — | 0.0% | 42.8% | 5.2% | 0.7% | -92.2% | 4266.3% | 52.3% | 18.7% | 721.0% | |
| Stock Issuance | $23.3M | $56.4M | $86.9M | $150.9K | $1.5M | $683.0K | $5.8M | $16.1M | $5.0M | $39.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $395.4K | $329.2K | $1.3M | $5.0M | $7.8M | $17.0M | $444.5K | $489.4K | $478.1K | $412.0K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | 98.8% | -523.2% | — | — | |
| Operating Margin % | — | — | — | — | — | — | -2652.8% | -953.0% | — | — | |
| Net Margin % | — | — | — | — | — | — | -2449.6% | -862.4% | — | — | |
| EBITDA Margin % | — | — | — | — | — | — | -2448.4% | -860.9% | — | — | |
| FCF Margin % | — | — | — | — | — | — | -2103.9% | -903.3% | — | — | |
| ROE % | 42.5% | 30.2% | -22.6% | -69.7% | -73.8% | -439.3% | -78.2% | -67.1% | -101.3% | -44.3% | |
| ROA % | -61.3% | -23.5% | -21.0% | -58.1% | -64.3% | -373.6% | -63.1% | -54.0% | -79.1% | -36.4% | |
| ROIC % | -77.5% | -27.0% | -23.7% | -67.9% | -75.3% | -420.7% | -84.7% | -69.5% | -100.5% | -43.9% | |
| R&D / Revenue % | — | — | — | — | — | — | 1307.8% | 623.2% | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 157.6% | -100.0% | |
| Gross Profit | 0.0% | -4.8% | -1947.3% | -34.9% | -18.3% | -5937.4% | 103.5% | -1464.3% | 100.0% | |
| Operating Income | 0.0% | -4.0% | -79.2% | -78.8% | 29.1% | -202.8% | 86.4% | 7.4% | 7.6% | |
| Net Income | 0.0% | -2.2% | -80.7% | -92.1% | 32.2% | -208.4% | 87.3% | 9.3% | 2.8% | |
| EPS (Diluted) | 0.0% | -2.2% | -19.1% | -92.6% | 31.1% | -3798.5% | 99.7% | 40.5% | 17.9% | |
| Operating Cash Flow | 0.0% | -8.9% | -75.1% | -56.5% | 9.8% | 33.6% | 51.3% | -11.3% | 4.9% | |
| Free Cash Flow | 0.0% | -8.9% | -75.3% | -56.4% | 9.9% | 33.6% | 50.9% | -10.6% | 5.0% | |
| R&D Expense | 0.0% | 6.0% | 47.6% | 80.8% | -36.9% | 286.8% | -91.7% | 22.8% | -24.8% | |
| SG&A Expense | 0.0% | -6.7% | 267.1% | 77.3% | -9.3% | 54.8% | -59.8% | -23.3% | 0.3% | |
| Total Assets | 0.0% | 166.6% | 102.4% | -30.5% | -38.8% | -46.9% | -24.9% | 5.9% | -33.6% | |
| Book Value / Share | 0.0% | -43.8% | 269.2% | -40.8% | -36.5% | 565.4% | -98.4% | -30.6% | -45.7% | |
| Debt | 0.0% | 0.0% | 0.0% | -38.5% | -43.2% | -100.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 42.8% | 5.2% | 0.7% | -92.2% | 4266.3% | 52.3% | 18.7% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.81
10Y Low / Med / High0.02 / 0.94 / 7.42
EV/EBITDA2.16
10Y Low / Med / High0.32 / 0.72 / 0.76
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$2.14
Tangible Book / Share
$0.64
Net Current Assets / Share
$2.68
Graham Net-Net
$0.62
Cash / Share
$0.71
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -19.00 | -18.59 | -34.92 | -1.94 | -1.65 | -0.00 | -1.19 | -1.40 | -0.44 | -0.74 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.15 | 12.06 | 0.00 | 0.00 | |
| P/B Ratio | -8.07 | -5.61 | 7.42 | 1.34 | 1.23 | 0.02 | 0.93 | 0.94 | 0.45 | 0.81 | |
| EV/EBITDA | -17.40 | -14.36 | -28.42 | -0.29 | -0.22 | 0.76 | 0.32 | 0.37 | 0.72 | 2.16 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.89 | -3.14 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-11.79
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $817.0K | $2.3M | $4.0M |
| Net Income | -$2.1M | -$2.5M | -$2.2M |
| EPS | $-0.32 | $-0.35 | $-0.35 |
| # Analysts (EPS) | 2 | 3 | 3 |